Deucravacitinib treatment did not affect immune response to SARS-Cov-2 vaccines and infection in patients with plaque psoriasis: results from the Phase 3 POETYK long-term extension trial

被引：0
|
作者：
不详
机构：
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
D O I：
10.1093/bjd/ljae360.144
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P114
引用
收藏
页数：1
相关论文
共 50 条
  • [41] LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY
    Isnardi, C. A.
    Alfaro, M. A.
    Virasoro, B. M.
    Gomez, G.
    D'angelo, M. E.
    Saurit, V.
    Petkovic, I. E.
    Quintana, R.
    Tissera, Y.
    Pisoni, C.
    Berbotto, G.
    Salinas, M. Haye
    Ornella, S.
    Pera, M.
    Reyes, A. A.
    Baez, R.
    Pereira, D. A.
    Alle, G.
    Coello, V. V. Castro
    Alba, P.
    Cogo, A. K.
    Alonso, C. G.
    Gobbi, C.
    Yanzi, J. Gallino
    Pons-Estel, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [42] Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Thaci, Diamant
    Puig, Luis
    Merola, Joseph F.
    Jullien, Denis
    Costanzo, Antonio
    Wang, Maggie
    Deherder, Delphine
    Lopez Pinto, Jose M.
    Lebwohl, Mark
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4733 - 4735
  • [43] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
    Papp, Kim A.
    Krueger, James G.
    Feldman, Steven R.
    Langley, Richard G.
    Thaci, Diamant
    Torii, Hideshi
    Tyring, Stephen
    Wolk, Robert
    Gardner, Annie
    Mebus, Charles
    Tan, Huaming
    Luo, Yingchun
    Gupta, Pankaj
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
  • [44] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [45] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials
    Kearney, Niamh
    Pink, Andrew
    Hoyt, Kim
    Kisa, Renata M.
    Banerjee, Subhashis
    Rogers, Alexandra
    Mullan, Jill
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I61
  • [46] Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase
    Al-Samkari, Hanny
    Aggarwal, Kavita
    Vredenburg, Michael
    Tian, Wei
    Allen, Lee F.
    BLOOD, 2019, 134
  • [47] LONG-TERM EFFICACY OF GUSELKUMAB TREATMENT AFTER DRUG WITHDRAWAL AND RETREATMENT IN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS: RESULTS FROM VOYAGE 2
    Gordon, Kenneth
    Armstrong, April
    Foley, Peter
    Wasfi, Yasmine
    Song, Michael
    Shen, Yaung-Kaung
    Li, Shu
    Munoz-Elias, Ernesto J.
    Randazzo, Bruce
    Reich, Kristian
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 23
  • [48] Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL)
    Ruetalo, Natalia
    Flehmig, Bertram
    Schindler, Michael
    Pridzun, Lutz
    Haage, Angelika
    Reichenbaecher, Marija
    Kirchner, Thomas
    Kirchner, Teresa
    Klingel, Karin
    Ranke, Michael B.
    Normann, Andrea
    VIRUSES-BASEL, 2021, 13 (12):
  • [49] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [50] Reply to Albulushi et al.dAbsence d Absence of Pericarditis Recurrence in RilonaceptTreated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From RHAPSODY Long-term Extension
    Brucato, Antonio
    Imazio, Massimo
    Paolini, John F.
    CJC OPEN, 2024, 6 (08) : 1033 - 1034
12345